| Ytd | -85.42% | |
| 1y | -39.20% |
| Open | 1.03 | Prev Close | 1.04 | Low | 0.96 | High | 1.05 | Mkt Cap | 15.18M |
| Vol | 121.96K | Avg Vol | 1.28M | EPS | -1.31 | P/E | N/A | Forward P/E | -1.69 |
| Beta | 1.20 | Short Ratio | 1.68 | Inst. Own | 43.87% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 0.74 | 200-d Avg | 2.28 | 1yr Est | 17.00 |
CALC News
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 168.2% to $7.94 during Friday&
Gainers INVO Fertility (NASDAQ:IVF) shares moved upwards by 67.3% to $2.08 during Friday's regu
Gainers Pulsenmore (NASDAQ:PLSM) shares moved upwards by 160.5% to $8.88 during Wednesday's reg
FDA raises no objections to CalciMedica revised Phase 2 KOURAGE trial, allowing Auxora dosing to res
FDX: -7% | FedEx shares are trading lower. The company reported Q4 financial results. LFS: 42% | LEI
The financing includes participation from new and existing investors, including members of CalciMedi
CalciMedica, Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage b
Proceeds expected to support a focused pulmonary hypertension strategy, including a Phase 1b proof-o
FDA reviewed a protocol amendment and interim safety data from the KOURAGE trial evaluating Auxora i
CalciMedica (NASDAQ:CALC) reported quarterly earnings of $0.30 per share which beat the analyst cons
FDA feedback on the Auxora™ pivotal program in acute pancreatitis and potential future development i
Oppenheimer analyst Leland Gershell maintains CalciMedica (NASDAQ:CALC) with a Outperform and low
CalciMedica (NASDAQ:CALC) reported quarterly losses of $(0.69) per share which missed the analyst co
Internal and external reviews of all available safety data from the Phase 2 KOURAGE trial in acute k
CalciMedica, Inc. (NASDAQ: CALC) shares are down on Wednesday after the company announced the discon
CalciMedica shares fell after the company stopped its Phase 2 KOURAGE trial for Auxora due to safety
During a prescheduled interim data review, the IDMC identified a safety concern that, in its view, w
Safety concern warrants reevaluation of study design, including enrollment criteria Potential future
EADSY lands a firm order for 30 A320neo aircraft from CALC, reinforcing strong global demand for its
CalciMedica Inc. (NASDAQ: CALC - Get Free Report) traded down 2.1% during trading on Tuesday. The co
CalciMedica (NASDAQ:CALC) reported quarterly losses of $(0.52) per share which missed the analyst co
Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) with respiratory
Preclinical data support CRAC channel inhibitor, CM5480, as a potential first-in-class, differentiat
Treatment with Auxora significantly reduced IL-17–related inflammation in both kidney and lung, sign
AI tools will allow CalciMedica to analyze Phase 2 datasets to refine the target patient populations
LA JOLLA, Calif. , Sept. 2, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (
Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) with respiratory
LA JOLLA, Calif. , July 8, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (N
Publication includes previously announced preclinical data of Auxora™ in acute kidney injury (AKI) m
LA JOLLA, Calif. , June 12, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (
Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) and respiratory
LA JOLLA, Calif. , April 17, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company")
CalciMedica Inc. (CALC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism abou